Reports
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States
Americas
Future Market Insights, Inc.
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States
MEA
Future Market Insights
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom
Asia Pacific
Future Market Insights
IndiaLand Global Tech Park, Unit UG-1, Behind Grand HighStreet, Phase 1, Hinjawadi, MH, Pune – 411057, India
The benign prostatic hyperplasia (BPH) prostate treatment market is anticipated to be worth US$ 33,031.10 million in 2024. The market is expected to grow at a steady rate over the period from 2024 to 2034, with a CAGR of 3.6%. By the end of the forecast period, the market value is predicted to hit US$ 47,045.80 million.
Attributes | Details |
---|---|
Benign Prostatic Hyperplasia (BPH) Prostate Treatment Market Value for 2024 | US$ 33,031.10 million |
Projected Market Value for 2034 | US$ 47,045.80 million |
Value-based CAGR of Market for 2024 to 2034 | 3.6% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Aside from the benign prostatic hyperplasia (BPH) prostate treatment market, analysis has been done on two other related markets. The markets by name are the prostate health market and the prostate cancer market.
Consumers becoming more knowledgeable about prostate health is driving the prostate health market. Development in health infrastructure is also aiding the prostate health market’s growth.
Development of new oral therapies like darolutamide (Nubeqa), and enzalutamide (Xtandi) is increasing the success rate of prostate cancer treatments. Government initiatives to raise awareness about prostate cancer are also benefitting the market.
Benign Prostatic Hyperplasia (BPH) Prostate Treatment Market:
Attributes | Benign Prostatic Hyperplasia (BPH) Prostate Treatment Market |
---|---|
Value-based CAGR (2024 to 2034) | 3.6% |
Projected Market Value (2034) | US$ 47,045.80 million |
Market Trends |
|
Restraint | Rising costs of BPH treatment |
Growth Factors |
|
Prostate Health Market:
Attributes | Prostate Health Market |
---|---|
Value-based CAGR (2024 to 2034) | 9.2% |
Market Trend | Increase in public and private sector funding for prostate-related research |
Restraint | Disdain towards side effects caused by prostate health treatments |
Growth Factor | Rise in geriatric population |
Prostate Cancer Market:
Attributes | Prostate Cancer Market |
---|---|
Value-based CAGR (2024 to 2034) | 8.5% |
Market Trend | Use of AI tools to manage prostate cancer treatments |
Restraint | Lack of skilled personnel to operate machinery used in prostate cancer treatments |
Growth Factors | Betterment of health infrastructure in developing nations |
Drugs continue to be the preferred treatment type for BPH. Institutional sales top the distribution channel segment.
For 2024, drugs are expected to account for 65.2% of the market share by treatment type. Some of the key drivers for the increasing use of drugs in BPH treatment are:
Attributes | Details |
---|---|
Top Treatment Type | Drugs |
Market Share (2024) | 65.2% |
Institutional sales are anticipated to account for 64.7% of the market share in 2024. Some of the key drivers for the progress of institutional sales include:
Attributes | Details |
---|---|
Top Distribution Channel | Institutional Sales |
Market Share (2024) | 64.7% |
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The increasing geriatric population is contributing to the market’s acceleration in North America. The presence of a wide variety of treatments is also propelling the benign prostatic hyperplasia (BPH) prostate treatment industry in North America.
Advancement of research institutions is lending a helping hand to the progress of the market in the region. The focus on the technological development of healthcare companies in the region is making sure BPH treatment keeps up with the times in Europe.
Countries | CAGR |
---|---|
United States | 4.0% |
Canada | 3.1% |
United Kingdom | 3.7% |
France | 3.3% |
Italy | 3.5% |
The market is set to register a CAGR of 4.0% in the United States for the forecast period. The key drivers for growth are:
The CAGR for the benign prostatic hyperplasia (BPH) prostate treatment market in Canada is tipped to be 3.1% over the forecast period. Some of the key factors driving the growth are:
The CAGR for the benign prostatic hyperplasia (BPH) prostate treatment market in the United Kingdom is tipped to be 3.7% over the forecast period. Some of the key factors driving the growth are:
The market is expected to register a CAGR of 3.3% in France for the forecast period. Some of the key trends include:
The market is expected to register a CAGR of 3.5% in Italy over the forecast period. Some of the key trends include:
The benign prostatic hyperplasia (BPH) prostate treatment market is competitive, though a few companies are prominent in the market. One of the well-established companies in the market is Pfizer Inc., who are concentrated on expansion through its alpha-blockers range.
Other players in the market are implementing strategies such as acquisitions and mergers to get a competitive edge. Research and development are also given importance by these market players.
Recent Developments in the Benign Prostatic Hyperplasia (BPH) Prostate Treatment Market
The benign prostatic hyperplasia (BPH) prostate treatment market size is expected to be worth US$ 33,031.10 million in 2024.
The benign prostatic hyperplasia (BPH) prostate treatment market is estimated to get as big as US$ 47,045.80 million in 2034.
The CAGR of the benign prostatic hyperplasia (BPH) prostate treatment market during the 2024 to 2034 period in the United States is estimated to be 4.0%.
The benign prostatic hyperplasia (BPH) prostate treatment market can be divided into the following segments: treatment type and distribution channel.
The benign prostatic hyperplasia (BPH) prostate treatment market is expected to grow at a CAGR of 3.6% over the period from 2024 to 2034.
Pfizer Inc., NxThera Inc., NeoTract Inc., and Sanofi S.A. are some of the key companies in the benign prostatic hyperplasia (BPH) prostate treatment Market.
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2019 to 2023 and Forecast, 2024 to 2034 4.1. Historical Market Size Value (US$ Million) Analysis, 2019 to 2023 4.2. Current and Future Market Size Value (US$ Million) Projections, 2024 to 2034 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Treatment Type 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Treatment Type, 2019 to 2023 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment Type, 2024 to 2034 5.3.1. BPH Drugs 5.3.1.1. Alpha Blockers 5.3.1.2. 5-Aplha Reductase Inhibitors 5.3.1.3. Phosphodiesterase-5 (PDE-5) Inhibitors 5.3.1.4. Muscarinic Receptor Antagonist (MRA) 5.3.1.5. Combination Drug 5.3.2. BPH Devices 5.3.2.1. Prostatic Stents 5.3.2.2. Suture Base Implant Systems 5.3.2.3. Transurethral RF Thermal Therapy Devices 5.4. Y-o-Y Growth Trend Analysis By Treatment Type, 2019 to 2023 5.5. Absolute $ Opportunity Analysis By Treatment Type, 2024 to 2034 6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Distribution Channel 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2019 to 2023 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2024 to 2034 6.3.1. Institutional Sales 6.3.1.1. Hospitals 6.3.1.2. Ambulatory Surgical Centres 6.3.1.3. Specialty Clinics 6.3.2. Retail Sales 6.3.2.1. Retail Pharmacies 6.3.2.2. Drug Stores 6.3.3. Online Pharmacies 6.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2019 to 2023 6.5. Absolute $ Opportunity Analysis By Distribution Channel, 2024 to 2034 7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Region 7.1. Introduction 7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2019 to 2023 7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2024 to 2034 7.3.1. North America 7.3.2. Latin America 7.3.3. Western Europe 7.3.4. Eastern Europe 7.3.5. South Asia and Pacific 7.3.6. East Asia 7.3.7. Middle East and Africa 7.4. Market Attractiveness Analysis By Region 8. North America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023 8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034 8.2.1. By Country 8.2.1.1. USA 8.2.1.2. Canada 8.2.2. By Treatment Type 8.2.3. By Distribution Channel 8.3. Market Attractiveness Analysis 8.3.1. By Country 8.3.2. By Treatment Type 8.3.3. By Distribution Channel 8.4. Key Takeaways 9. Latin America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023 9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034 9.2.1. By Country 9.2.1.1. Brazil 9.2.1.2. Mexico 9.2.1.3. Rest of Latin America 9.2.2. By Treatment Type 9.2.3. By Distribution Channel 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Treatment Type 9.3.3. By Distribution Channel 9.4. Key Takeaways 10. Western Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034 10.2.1. By Country 10.2.1.1. Germany 10.2.1.2. UK 10.2.1.3. France 10.2.1.4. Spain 10.2.1.5. Italy 10.2.1.6. Rest of Western Europe 10.2.2. By Treatment Type 10.2.3. By Distribution Channel 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Treatment Type 10.3.3. By Distribution Channel 10.4. Key Takeaways 11. Eastern Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034 11.2.1. By Country 11.2.1.1. Poland 11.2.1.2. Russia 11.2.1.3. Czech Republic 11.2.1.4. Romania 11.2.1.5. Rest of Eastern Europe 11.2.2. By Treatment Type 11.2.3. By Distribution Channel 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Treatment Type 11.3.3. By Distribution Channel 11.4. Key Takeaways 12. South Asia and Pacific Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034 12.2.1. By Country 12.2.1.1. India 12.2.1.2. Bangladesh 12.2.1.3. Australia 12.2.1.4. New Zealand 12.2.1.5. Rest of South Asia and Pacific 12.2.2. By Treatment Type 12.2.3. By Distribution Channel 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Treatment Type 12.3.3. By Distribution Channel 12.4. Key Takeaways 13. East Asia Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034 13.2.1. By Country 13.2.1.1. China 13.2.1.2. Japan 13.2.1.3. South Korea 13.2.2. By Treatment Type 13.2.3. By Distribution Channel 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Treatment Type 13.3.3. By Distribution Channel 13.4. Key Takeaways 14. Middle East and Africa Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023 14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034 14.2.1. By Country 14.2.1.1. GCC Countries 14.2.1.2. South Africa 14.2.1.3. Israel 14.2.1.4. Rest of MEA 14.2.2. By Treatment Type 14.2.3. By Distribution Channel 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Treatment Type 14.3.3. By Distribution Channel 14.4. Key Takeaways 15. Key Countries Market Analysis 15.1. USA 15.1.1. Market Share Analysis, 2023 15.1.1.1. By Treatment Type 15.1.1.2. By Distribution Channel 15.2. Canada 15.2.1. Market Share Analysis, 2023 15.2.1.1. By Treatment Type 15.2.1.2. By Distribution Channel 15.3. Brazil 15.3.1. Market Share Analysis, 2023 15.3.1.1. By Treatment Type 15.3.1.2. By Distribution Channel 15.4. Mexico 15.4.1. Market Share Analysis, 2023 15.4.1.1. By Treatment Type 15.4.1.2. By Distribution Channel 15.5. Germany 15.5.1. Market Share Analysis, 2023 15.5.1.1. By Treatment Type 15.5.1.2. By Distribution Channel 15.6. UK 15.6.1. Market Share Analysis, 2023 15.6.1.1. By Treatment Type 15.6.1.2. By Distribution Channel 15.7. France 15.7.1. Market Share Analysis, 2023 15.7.1.1. By Treatment Type 15.7.1.2. By Distribution Channel 15.8. Spain 15.8.1. Market Share Analysis, 2023 15.8.1.1. By Treatment Type 15.8.1.2. By Distribution Channel 15.9. Italy 15.9.1. Market Share Analysis, 2023 15.9.1.1. By Treatment Type 15.9.1.2. By Distribution Channel 15.10. Poland 15.10.1. Market Share Analysis, 2023 15.10.1.1. By Treatment Type 15.10.1.2. By Distribution Channel 15.11. Russia 15.11.1. Market Share Analysis, 2023 15.11.1.1. By Treatment Type 15.11.1.2. By Distribution Channel 15.12. Czech Republic 15.12.1. Market Share Analysis, 2023 15.12.1.1. By Treatment Type 15.12.1.2. By Distribution Channel 15.13. Romania 15.13.1. Market Share Analysis, 2023 15.13.1.1. By Treatment Type 15.13.1.2. By Distribution Channel 15.14. India 15.14.1. Market Share Analysis, 2023 15.14.1.1. By Treatment Type 15.14.1.2. By Distribution Channel 15.15. Bangladesh 15.15.1. Market Share Analysis, 2023 15.15.1.1. By Treatment Type 15.15.1.2. By Distribution Channel 15.16. Australia 15.16.1. Market Share Analysis, 2023 15.16.1.1. By Treatment Type 15.16.1.2. By Distribution Channel 15.17. New Zealand 15.17.1. Market Share Analysis, 2023 15.17.1.1. By Treatment Type 15.17.1.2. By Distribution Channel 15.18. China 15.18.1. Market Share Analysis, 2023 15.18.1.1. By Treatment Type 15.18.1.2. By Distribution Channel 15.19. Japan 15.19.1. Market Share Analysis, 2023 15.19.1.1. By Treatment Type 15.19.1.2. By Distribution Channel 15.20. South Korea 15.20.1. Market Share Analysis, 2023 15.20.1.1. By Treatment Type 15.20.1.2. By Distribution Channel 15.21. GCC Countries 15.21.1. Market Share Analysis, 2023 15.21.1.1. By Treatment Type 15.21.1.2. By Distribution Channel 15.22. South Africa 15.22.1. Market Share Analysis, 2023 15.22.1.1. By Treatment Type 15.22.1.2. By Distribution Channel 15.23. Israel 15.23.1. Market Share Analysis, 2023 15.23.1.1. By Treatment Type 15.23.1.2. By Distribution Channel 16. Market Structure Analysis 16.1. Competition Dashboard 16.2. Competition Benchmarking 16.3. Market Share Analysis of Top Players 16.3.1. By Regional 16.3.2. By Treatment Type 16.3.3. By Distribution Channel 17. Competition Analysis 17.1. Competition Deep Dive 17.1.1. Pfizer Inc. 17.1.1.1. Overview 17.1.1.2. Product Portfolio 17.1.1.3. Profitability by Market Segments 17.1.1.4. Sales Footprint 17.1.1.5. Strategy Overview 17.1.1.5.1. Marketing Strategy 17.1.2. NxThera Inc. 17.1.2.1. Overview 17.1.2.2. Product Portfolio 17.1.2.3. Profitability by Market Segments 17.1.2.4. Sales Footprint 17.1.2.5. Strategy Overview 17.1.2.5.1. Marketing Strategy 17.1.3. NeoTract Inc. 17.1.3.1. Overview 17.1.3.2. Product Portfolio 17.1.3.3. Profitability by Market Segments 17.1.3.4. Sales Footprint 17.1.3.5. Strategy Overview 17.1.3.5.1. Marketing Strategy 17.1.4. Sanofi S.A 17.1.4.1. Overview 17.1.4.2. Product Portfolio 17.1.4.3. Profitability by Market Segments 17.1.4.4. Sales Footprint 17.1.4.5. Strategy Overview 17.1.4.5.1. Marketing Strategy 17.1.5. GlaxoSmithKline Plc. 17.1.5.1. Overview 17.1.5.2. Product Portfolio 17.1.5.3. Profitability by Market Segments 17.1.5.4. Sales Footprint 17.1.5.5. Strategy Overview 17.1.5.5.1. Marketing Strategy 17.1.6. Allergan Plc. 17.1.6.1. Overview 17.1.6.2. Product Portfolio 17.1.6.3. Profitability by Market Segments 17.1.6.4. Sales Footprint 17.1.6.5. Strategy Overview 17.1.6.5.1. Marketing Strategy 17.1.7. Teva Pharmaceutical Industries Ltd. 17.1.7.1. Overview 17.1.7.2. Product Portfolio 17.1.7.3. Profitability by Market Segments 17.1.7.4. Sales Footprint 17.1.7.5. Strategy Overview 17.1.7.5.1. Marketing Strategy 17.1.8. Mylan N.V. 17.1.8.1. Overview 17.1.8.2. Product Portfolio 17.1.8.3. Profitability by Market Segments 17.1.8.4. Sales Footprint 17.1.8.5. Strategy Overview 17.1.8.5.1. Marketing Strategy 17.1.9. Eli Lily & Company 17.1.9.1. Overview 17.1.9.2. Product Portfolio 17.1.9.3. Profitability by Market Segments 17.1.9.4. Sales Footprint 17.1.9.5. Strategy Overview 17.1.9.5.1. Marketing Strategy 17.1.10. Cardinal Health Inc. 17.1.10.1. Overview 17.1.10.2. Product Portfolio 17.1.10.3. Profitability by Market Segments 17.1.10.4. Sales Footprint 17.1.10.5. Strategy Overview 17.1.10.5.1. Marketing Strategy 18. Assumptions & Acronyms Used 19. Research Methodology
Table 1: Global Market Value (US$ Million) Forecast by Region, 2019 to 2034 Table 2: Global Market Value (US$ Million) Forecast by Treatment Type, 2019 to 2034 Table 3: Global Market Value (US$ Million) Forecast by Distribution Channel, 2019 to 2034 Table 4: North America Market Value (US$ Million) Forecast by Country, 2019 to 2034 Table 5: North America Market Value (US$ Million) Forecast by Treatment Type, 2019 to 2034 Table 6: North America Market Value (US$ Million) Forecast by Distribution Channel, 2019 to 2034 Table 7: Latin America Market Value (US$ Million) Forecast by Country, 2019 to 2034 Table 8: Latin America Market Value (US$ Million) Forecast by Treatment Type, 2019 to 2034 Table 9: Latin America Market Value (US$ Million) Forecast by Distribution Channel, 2019 to 2034 Table 10: Western Europe Market Value (US$ Million) Forecast by Country, 2019 to 2034 Table 11: Western Europe Market Value (US$ Million) Forecast by Treatment Type, 2019 to 2034 Table 12: Western Europe Market Value (US$ Million) Forecast by Distribution Channel, 2019 to 2034 Table 13: Eastern Europe Market Value (US$ Million) Forecast by Country, 2019 to 2034 Table 14: Eastern Europe Market Value (US$ Million) Forecast by Treatment Type, 2019 to 2034 Table 15: Eastern Europe Market Value (US$ Million) Forecast by Distribution Channel, 2019 to 2034 Table 16: South Asia and Pacific Market Value (US$ Million) Forecast by Country, 2019 to 2034 Table 17: South Asia and Pacific Market Value (US$ Million) Forecast by Treatment Type, 2019 to 2034 Table 18: South Asia and Pacific Market Value (US$ Million) Forecast by Distribution Channel, 2019 to 2034 Table 19: East Asia Market Value (US$ Million) Forecast by Country, 2019 to 2034 Table 20: East Asia Market Value (US$ Million) Forecast by Treatment Type, 2019 to 2034 Table 21: East Asia Market Value (US$ Million) Forecast by Distribution Channel, 2019 to 2034 Table 22: Middle East and Africa Market Value (US$ Million) Forecast by Country, 2019 to 2034 Table 23: Middle East and Africa Market Value (US$ Million) Forecast by Treatment Type, 2019 to 2034 Table 24: Middle East and Africa Market Value (US$ Million) Forecast by Distribution Channel, 2019 to 2034
Figure 1: Global Market Value (US$ Million) by Treatment Type, 2024 to 2034 Figure 2: Global Market Value (US$ Million) by Distribution Channel, 2024 to 2034 Figure 3: Global Market Value (US$ Million) by Region, 2024 to 2034 Figure 4: Global Market Value (US$ Million) Analysis by Region, 2019 to 2034 Figure 5: Global Market Value Share (%) and BPS Analysis by Region, 2024 to 2034 Figure 6: Global Market Y-o-Y Growth (%) Projections by Region, 2024 to 2034 Figure 7: Global Market Value (US$ Million) Analysis by Treatment Type, 2019 to 2034 Figure 8: Global Market Value Share (%) and BPS Analysis by Treatment Type, 2024 to 2034 Figure 9: Global Market Y-o-Y Growth (%) Projections by Treatment Type, 2024 to 2034 Figure 10: Global Market Value (US$ Million) Analysis by Distribution Channel, 2019 to 2034 Figure 11: Global Market Value Share (%) and BPS Analysis by Distribution Channel, 2024 to 2034 Figure 12: Global Market Y-o-Y Growth (%) Projections by Distribution Channel, 2024 to 2034 Figure 13: Global Market Attractiveness by Treatment Type, 2024 to 2034 Figure 14: Global Market Attractiveness by Distribution Channel, 2024 to 2034 Figure 15: Global Market Attractiveness by Region, 2024 to 2034 Figure 16: North America Market Value (US$ Million) by Treatment Type, 2024 to 2034 Figure 17: North America Market Value (US$ Million) by Distribution Channel, 2024 to 2034 Figure 18: North America Market Value (US$ Million) by Country, 2024 to 2034 Figure 19: North America Market Value (US$ Million) Analysis by Country, 2019 to 2034 Figure 20: North America Market Value Share (%) and BPS Analysis by Country, 2024 to 2034 Figure 21: North America Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034 Figure 22: North America Market Value (US$ Million) Analysis by Treatment Type, 2019 to 2034 Figure 23: North America Market Value Share (%) and BPS Analysis by Treatment Type, 2024 to 2034 Figure 24: North America Market Y-o-Y Growth (%) Projections by Treatment Type, 2024 to 2034 Figure 25: North America Market Value (US$ Million) Analysis by Distribution Channel, 2019 to 2034 Figure 26: North America Market Value Share (%) and BPS Analysis by Distribution Channel, 2024 to 2034 Figure 27: North America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2024 to 2034 Figure 28: North America Market Attractiveness by Treatment Type, 2024 to 2034 Figure 29: North America Market Attractiveness by Distribution Channel, 2024 to 2034 Figure 30: North America Market Attractiveness by Country, 2024 to 2034 Figure 31: Latin America Market Value (US$ Million) by Treatment Type, 2024 to 2034 Figure 32: Latin America Market Value (US$ Million) by Distribution Channel, 2024 to 2034 Figure 33: Latin America Market Value (US$ Million) by Country, 2024 to 2034 Figure 34: Latin America Market Value (US$ Million) Analysis by Country, 2019 to 2034 Figure 35: Latin America Market Value Share (%) and BPS Analysis by Country, 2024 to 2034 Figure 36: Latin America Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034 Figure 37: Latin America Market Value (US$ Million) Analysis by Treatment Type, 2019 to 2034 Figure 38: Latin America Market Value Share (%) and BPS Analysis by Treatment Type, 2024 to 2034 Figure 39: Latin America Market Y-o-Y Growth (%) Projections by Treatment Type, 2024 to 2034 Figure 40: Latin America Market Value (US$ Million) Analysis by Distribution Channel, 2019 to 2034 Figure 41: Latin America Market Value Share (%) and BPS Analysis by Distribution Channel, 2024 to 2034 Figure 42: Latin America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2024 to 2034 Figure 43: Latin America Market Attractiveness by Treatment Type, 2024 to 2034 Figure 44: Latin America Market Attractiveness by Distribution Channel, 2024 to 2034 Figure 45: Latin America Market Attractiveness by Country, 2024 to 2034 Figure 46: Western Europe Market Value (US$ Million) by Treatment Type, 2024 to 2034 Figure 47: Western Europe Market Value (US$ Million) by Distribution Channel, 2024 to 2034 Figure 48: Western Europe Market Value (US$ Million) by Country, 2024 to 2034 Figure 49: Western Europe Market Value (US$ Million) Analysis by Country, 2019 to 2034 Figure 50: Western Europe Market Value Share (%) and BPS Analysis by Country, 2024 to 2034 Figure 51: Western Europe Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034 Figure 52: Western Europe Market Value (US$ Million) Analysis by Treatment Type, 2019 to 2034 Figure 53: Western Europe Market Value Share (%) and BPS Analysis by Treatment Type, 2024 to 2034 Figure 54: Western Europe Market Y-o-Y Growth (%) Projections by Treatment Type, 2024 to 2034 Figure 55: Western Europe Market Value (US$ Million) Analysis by Distribution Channel, 2019 to 2034 Figure 56: Western Europe Market Value Share (%) and BPS Analysis by Distribution Channel, 2024 to 2034 Figure 57: Western Europe Market Y-o-Y Growth (%) Projections by Distribution Channel, 2024 to 2034 Figure 58: Western Europe Market Attractiveness by Treatment Type, 2024 to 2034 Figure 59: Western Europe Market Attractiveness by Distribution Channel, 2024 to 2034 Figure 60: Western Europe Market Attractiveness by Country, 2024 to 2034 Figure 61: Eastern Europe Market Value (US$ Million) by Treatment Type, 2024 to 2034 Figure 62: Eastern Europe Market Value (US$ Million) by Distribution Channel, 2024 to 2034 Figure 63: Eastern Europe Market Value (US$ Million) by Country, 2024 to 2034 Figure 64: Eastern Europe Market Value (US$ Million) Analysis by Country, 2019 to 2034 Figure 65: Eastern Europe Market Value Share (%) and BPS Analysis by Country, 2024 to 2034 Figure 66: Eastern Europe Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034 Figure 67: Eastern Europe Market Value (US$ Million) Analysis by Treatment Type, 2019 to 2034 Figure 68: Eastern Europe Market Value Share (%) and BPS Analysis by Treatment Type, 2024 to 2034 Figure 69: Eastern Europe Market Y-o-Y Growth (%) Projections by Treatment Type, 2024 to 2034 Figure 70: Eastern Europe Market Value (US$ Million) Analysis by Distribution Channel, 2019 to 2034 Figure 71: Eastern Europe Market Value Share (%) and BPS Analysis by Distribution Channel, 2024 to 2034 Figure 72: Eastern Europe Market Y-o-Y Growth (%) Projections by Distribution Channel, 2024 to 2034 Figure 73: Eastern Europe Market Attractiveness by Treatment Type, 2024 to 2034 Figure 74: Eastern Europe Market Attractiveness by Distribution Channel, 2024 to 2034 Figure 75: Eastern Europe Market Attractiveness by Country, 2024 to 2034 Figure 76: South Asia and Pacific Market Value (US$ Million) by Treatment Type, 2024 to 2034 Figure 77: South Asia and Pacific Market Value (US$ Million) by Distribution Channel, 2024 to 2034 Figure 78: South Asia and Pacific Market Value (US$ Million) by Country, 2024 to 2034 Figure 79: South Asia and Pacific Market Value (US$ Million) Analysis by Country, 2019 to 2034 Figure 80: South Asia and Pacific Market Value Share (%) and BPS Analysis by Country, 2024 to 2034 Figure 81: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034 Figure 82: South Asia and Pacific Market Value (US$ Million) Analysis by Treatment Type, 2019 to 2034 Figure 83: South Asia and Pacific Market Value Share (%) and BPS Analysis by Treatment Type, 2024 to 2034 Figure 84: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Treatment Type, 2024 to 2034 Figure 85: South Asia and Pacific Market Value (US$ Million) Analysis by Distribution Channel, 2019 to 2034 Figure 86: South Asia and Pacific Market Value Share (%) and BPS Analysis by Distribution Channel, 2024 to 2034 Figure 87: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Distribution Channel, 2024 to 2034 Figure 88: South Asia and Pacific Market Attractiveness by Treatment Type, 2024 to 2034 Figure 89: South Asia and Pacific Market Attractiveness by Distribution Channel, 2024 to 2034 Figure 90: South Asia and Pacific Market Attractiveness by Country, 2024 to 2034 Figure 91: East Asia Market Value (US$ Million) by Treatment Type, 2024 to 2034 Figure 92: East Asia Market Value (US$ Million) by Distribution Channel, 2024 to 2034 Figure 93: East Asia Market Value (US$ Million) by Country, 2024 to 2034 Figure 94: East Asia Market Value (US$ Million) Analysis by Country, 2019 to 2034 Figure 95: East Asia Market Value Share (%) and BPS Analysis by Country, 2024 to 2034 Figure 96: East Asia Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034 Figure 97: East Asia Market Value (US$ Million) Analysis by Treatment Type, 2019 to 2034 Figure 98: East Asia Market Value Share (%) and BPS Analysis by Treatment Type, 2024 to 2034 Figure 99: East Asia Market Y-o-Y Growth (%) Projections by Treatment Type, 2024 to 2034 Figure 100: East Asia Market Value (US$ Million) Analysis by Distribution Channel, 2019 to 2034 Figure 101: East Asia Market Value Share (%) and BPS Analysis by Distribution Channel, 2024 to 2034 Figure 102: East Asia Market Y-o-Y Growth (%) Projections by Distribution Channel, 2024 to 2034 Figure 103: East Asia Market Attractiveness by Treatment Type, 2024 to 2034 Figure 104: East Asia Market Attractiveness by Distribution Channel, 2024 to 2034 Figure 105: East Asia Market Attractiveness by Country, 2024 to 2034 Figure 106: Middle East and Africa Market Value (US$ Million) by Treatment Type, 2024 to 2034 Figure 107: Middle East and Africa Market Value (US$ Million) by Distribution Channel, 2024 to 2034 Figure 108: Middle East and Africa Market Value (US$ Million) by Country, 2024 to 2034 Figure 109: Middle East and Africa Market Value (US$ Million) Analysis by Country, 2019 to 2034 Figure 110: Middle East and Africa Market Value Share (%) and BPS Analysis by Country, 2024 to 2034 Figure 111: Middle East and Africa Market Y-o-Y Growth (%) Projections by Country, 2024 to 2034 Figure 112: Middle East and Africa Market Value (US$ Million) Analysis by Treatment Type, 2019 to 2034 Figure 113: Middle East and Africa Market Value Share (%) and BPS Analysis by Treatment Type, 2024 to 2034 Figure 114: Middle East and Africa Market Y-o-Y Growth (%) Projections by Treatment Type, 2024 to 2034 Figure 115: Middle East and Africa Market Value (US$ Million) Analysis by Distribution Channel, 2019 to 2034 Figure 116: Middle East and Africa Market Value Share (%) and BPS Analysis by Distribution Channel, 2024 to 2034 Figure 117: Middle East and Africa Market Y-o-Y Growth (%) Projections by Distribution Channel, 2024 to 2034 Figure 118: Middle East and Africa Market Attractiveness by Treatment Type, 2024 to 2034 Figure 119: Middle East and Africa Market Attractiveness by Distribution Channel, 2024 to 2034 Figure 120: Middle East and Africa Market Attractiveness by Country, 2024 to 2034
Recommendations
Explore Healthcare Insights
View Reports